Patents by Inventor Enrique Maria Ocio
Enrique Maria Ocio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250009715Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: June 14, 2024Publication date: January 9, 2025Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 12064417Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: December 19, 2022Date of Patent: August 20, 2024Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 12048688Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: December 22, 2022Date of Patent: July 30, 2024Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20230285363Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: December 19, 2022Publication date: September 14, 2023Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20230241033Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: December 22, 2022Publication date: August 3, 2023Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 11559516Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: March 25, 2021Date of Patent: January 24, 2023Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 11541038Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: August 14, 2020Date of Patent: January 3, 2023Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20210346351Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: March 25, 2021Publication date: November 11, 2021Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20210059989Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: August 14, 2020Publication date: March 4, 2021Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20200261534Abstract: The present invention relates to the field of oncology. More specifically, it relates to the use of peptidomimetic compounds in the treatment of multiple myeloma, especially in refractory or relapsing multiple myeloma and/or in combination with other antitumoral agents.Type: ApplicationFiled: September 10, 2018Publication date: August 20, 2020Inventors: Santiago ESTEBAN MARTÍN, Laura NEVOLA, Enrique María OCIO SAN MIGUEL, Patryk KRZEMINSKI, Mercedes GARAYOA
-
Patent number: 10744120Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 26, 2015Date of Patent: August 18, 2020Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20190343807Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: July 22, 2019Publication date: November 14, 2019Inventors: Thomas Mehrling, Enrique Maria Ocio
-
Patent number: 10406138Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 21, 2018Date of Patent: September 10, 2019Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20180369204Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: May 21, 2018Publication date: December 27, 2018Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20170296513Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: May 26, 2015Publication date: October 19, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20170151218Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: May 26, 2015Publication date: June 1, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
